

Site of Care Policy

Date of Origin: 10/1/2017

Versions: 10/17, 07/19, 11/20, 01/22, 06/22

I. Background

The Site of Care program, effective October 1, 2017, directs members to the most cost-effective, yet clinically appropriate location to receive their infusion(s) of select specialty medications as listed in section IV.

II. Scope

- A. Applicable to all Fully Insured Commercial members, Exchange members, select Medicaid members, select ASO groups, and all Texas Equal Funding members.
 1. New utilizers of these medications will be subject to the program requirements.
 2. Members currently using these medications will be subject to the program requirements upon prior authorization.

III. Program Requirements

- A. The Site of Care program requirements will be administered as part of the existing prior authorization program.
 - To begin requesting prior authorizations through the Magellan Rx self-service portal, visit ih.magellanrx.com/ and select “New Access Request-Provider” on the right side of the home page.
- B. All drugs in the Site of Care program require prior authorization.
- C. Requests for select specialty drugs as listed in section IV to be administered in a hospital outpatient setting will be directed to a preferred alternative site of care, such as a home infusion provider or a physician office. Infusions for these medications are excluded from payment when administered in a hospital outpatient infusion center.
- D. There are various infusion partners to support members across different geographies and groups with different benefit designs and/or provider preferences. If care is delivered outside of a professional office, preferred providers include:
 1. Emerging Health
 2. Option Care (Texas only)
 3. Oregon Health and Science University (OHSU) Home Infusion Services (OHSU employees only)

- E. To prevent a delay in care and allow adequate transition time for Moda members to an alternate infusion site, Site of Care program requirements will be waived for the first sixty (60) days only after prior authorization approval so that members can transition to a different infusion site.

IV. Drugs in Scope

- A. Select infused specialty medications included in the Site of Care program are subject to change. The most current list of drugs in scope of the program may be found here: https://www.modahealth.com/pdfs/medical/soc_auth_list.pdf
- B. Changes to the Drugs in Scope
 - 1. If currently available infused specialty medications are added to the Site of Care program medication list, prescribers will receive advanced notification per the terms of the provider contract with Moda.
 - 2. Newly available infused specialty medications may be added to the Site of Care program medication list upon FDA-approval.

V. Exceptions

- A. Exceptions to the Site of Care program requirements are reviewed through the prior authorization process and may be granted on a case-by-case basis based on medical necessity.